Amgen Inc. (AMGN) income statement
NASDAQ · Healthcare · Drug Manufacturers - General · 31,500 employees · CEO Robert A. Bradway
- Price
- $466.01 +1.15%
- Market cap
- $252B
- Enterprise value
- $295B
- Last report
- Q2 '26 filed 2026-08-05
- Next report
- 2026-11-03 EPS est. $5.79
Amgen Inc. (AMGN) reported revenue of $10.1B for Q2 '26 (+9.7% year on year), operating income of $3.51B (35.0% of revenue) and net income of $2.38B. Over the last four quarters revenue was $38.1B.
Income statement
| Income statement | Trend | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.9B | $8.2B | $7.45B | $8.39B | $8.5B | $9.09B | $8.15B | $9.17B | $9.56B | $9.9B | $8.62B | $10.1B | |
| Cost of revenue | $1.81B | $3.11B | $3.2B | $3.24B | $3.31B | $3.11B | $2.97B | $3.01B | $3.08B | $1.79B | $2.74B | $2.81B | |
| Gross profit | $5.1B | $5.08B | $4.25B | $5.15B | $5.19B | $5.97B | $5.18B | $6.16B | $6.48B | $8.11B | $5.87B | $7.24B | |
| Research & development | $1.08B | $1.53B | $1.34B | $1.45B | $1.45B | $1.72B | $1.49B | $1.74B | $1.9B | $2.15B | $1.72B | $1.87B | |
| Sales & marketing | $0 | $0 | $0 | $0 | $0 | $987M | $0 | $0 | $0 | $0 | $0 | $0 | |
| General & administrative | $0 | $0 | $0 | $0 | $0 | $891M | $0 | $0 | $0 | $0 | $0 | $0 | |
| Other operating expenses | $644M | $5M | $105M | $11M | $71M | $61M | $830M | $77M | $329M | $76M | -$113M | $116M | |
| Operating expenses | $3.08B | $3.81B | $3.26B | $3.24B | $3.15B | $3.66B | $4B | $3.51B | $3.95B | $4.16B | $3.21B | $3.73B | |
| Operating income | $2.02B | $1.27B | $991M | $1.91B | $2.05B | $2.31B | $1.18B | $2.64B | $2.53B | $3.94B | $2.67B | $3.51B | |
| Interest expense | $759M | $821M | $824M | $808M | $776M | $747M | $723M | $708M | $685M | $653M | $657M | $673M | |
| Other non-operating income (gains on investments, FX ...) | -$685M | -$402M | $235M | $307M | -$1.83B | $782M | -$1.52B | $368M | -$2.08B | $1.78B | -$75M | $73M | |
| Total non-operating income | -$74M | -$419M | -$1.06B | -$1.12B | $1.05B | -$1.53B | $795M | -$1.08B | $1.4B | -$2.43B | -$582M | -$746M | |
| Income before tax | $1.95B | $852M | -$68M | $794M | $3.1B | $782M | $1.97B | $1.57B | $3.92B | $1.51B | $2.08B | $2.77B | |
| Income tax | $217M | $85M | $45M | $48M | $271M | $155M | $243M | $136M | $705M | $181M | $265M | $393M | |
| Net income | $1.73B | $767M | -$113M | $746M | $2.83B | $627M | $1.73B | $1.43B | $3.22B | $1.33B | $1.82B | $2.38B | |
| EPS (basic) | $3.23 | $1.43 | -$0.21 | $1.39 | $5.27 | $1.17 | $3.22 | $2.66 | $5.98 | $2.47 | $3.37 | $4.40 | |
| EPS (diluted) | $3.22 | $1.42 | -$0.21 | $1.38 | $5.22 | $1.16 | $3.20 | $2.65 | $5.93 | $2.45 | $3.34 | $4.37 | |
| Shares (basic, weighted) | 535M | 535M | 536M | 537M | 537M | 541M | 538M | 538M | 538M | 539M | 540M | 540M | |
| Shares (diluted, weighted) | 538M | 540M | 536M | 541M | 542M | 542M | 541M | 541M | 542M | 543M | 544M | 544M | |
| Depreciation & amortization | $895M | $1.38B | $1.4B | $1.4B | $1.4B | $1.4B | $1.39B | $1.34B | $1.31B | $1.13B | $1.12B | $1.11B | |
| EBITDA | $3.6B | $3.05B | $2.16B | $3B | $5.27B | $2.93B | $4.08B | $3.62B | $5.91B | $3.3B | $3.86B | $4.55B |
| Income statement | Trend | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $23B | $22.8B | $23.7B | $23.4B | $25.4B | $26B | $26.3B | $28.2B | $33.4B | $36.7B | |
| Cost of revenue | $4.16B | $4.07B | $4.1B | $4.36B | $6.16B | $6.45B | $6.41B | $8.42B | $12.9B | $10.7B | |
| Gross profit | $18.8B | $18.8B | $19.6B | $19B | $19.3B | $19.5B | $19.9B | $19.8B | $20.6B | $26B | |
| Research & development | $3.84B | $3.56B | $3.74B | $4.12B | $4.21B | $6.32B | $4.43B | $4.78B | $5.96B | $6.97B | |
| Sales & marketing | $0 | $0 | $0 | $0 | $0 | $843M | $841M | $0 | $987M | $0 | |
| General & administrative | $0 | $0 | $0 | $0 | $0 | $4.53B | $4.57B | $0 | $6.11B | $0 | |
| Other operating expenses | $133M | $375M | $314M | $66M | $189M | $194M | $503M | $879M | $248M | $1.31B | |
| Operating expenses | $9.04B | $8.81B | $9.38B | $9.33B | $10.1B | $11.9B | $10.4B | $11.8B | $13.3B | $15.3B | |
| Operating income | $9.79B | $9.97B | $10.3B | $9.67B | $9.14B | $7.64B | $9.57B | $7.9B | $7.26B | $10.7B | |
| Interest income | $629M | $928M | $674M | $587M | $0 | $0 | $0 | $0 | $0 | $0 | |
| Interest expense | $1.26B | $1.3B | $1.39B | $1.29B | $1.26B | $1.2B | $1.41B | $2.88B | $3.16B | $2.76B | |
| Other non-operating income (gains on investments, FX ...) | -$629M | -$928M | -$674M | -$753M | -$256M | -$259M | $814M | -$2.83B | -$506M | -$1.06B | |
| Total non-operating income | -$631M | -$376M | -$718M | -$536M | -$1.01B | -$938M | -$2.22B | -$42M | -$2.65B | -$1.7B | |
| Income before tax | $9.16B | $9.6B | $9.55B | $9.14B | $8.13B | $6.7B | $7.35B | $7.86B | $4.61B | $8.98B | |
| Income tax | $1.44B | $7.62B | $1.15B | $1.3B | $869M | $808M | $794M | $1.14B | $519M | $1.27B | |
| Net income | $7.72B | $1.98B | $8.39B | $7.84B | $7.26B | $5.89B | $6.55B | $6.72B | $4.09B | $7.71B | |
| EPS (basic) | $10.32 | $2.71 | $12.70 | $12.96 | $12.40 | $10.34 | $12.18 | $12.56 | $7.62 | $14.33 | |
| EPS (diluted) | $10.24 | $2.69 | $12.62 | $12.88 | $12.31 | $10.28 | $12.11 | $12.49 | $7.56 | $14.23 | |
| Shares (basic, weighted) | 748M | 731M | 661M | 605M | 586M | 570M | 538M | 535M | 541M | 538M | |
| Shares (diluted, weighted) | 754M | 735M | 665M | 609M | 590M | 573M | 541M | 538M | 541M | 542M | |
| Depreciation & amortization | $2.11B | $1.96B | $1.95B | $2.21B | $3.6B | $3.4B | $3.42B | $4.07B | $5.59B | $5.17B | |
| EBITDA | $12.5B | $12.9B | $12.9B | $12.6B | $13B | $11.3B | $12.2B | $14.8B | $13.4B | $16.9B |
Standardised by Financial Modeling Prep from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.
Revenue, operating income and growth
quarterlyMargins
quarterlyCosts as % of revenue
quarterlyThe other statements
Sources
Statements, segment revenue, metrics, estimates: Financial Modeling Prep. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
Data as of 2026-11-01